Version May 2024
Note: Measure dose by a suitable radioactivity calibration system immediately prior to administration.
Radioimaging: IV: 10 mCi (370 MBq); maximum: 50 mcg mass dose
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
Refer to adult dosing.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
1% to 10%: Central nervous system: Headache (2%)
<1%: Anxiety, back pain, claustrophobia, dizziness, dysgeusia, fatigue, flushing, increased blood pressure, injection site reaction (including injection site hemorrhage, injection site irritation, and injection site pain), insomnia, musculoskeletal pain, nausea, neck pain, pruritus, rash at injection site, sensation of cold, urticaria
There are no contraindications listed within the manufacturer's labeling.
Concerns related to adverse effects:
• Malignancy: Patients are exposed to some radiation during treatment; large cumulative amounts of radiation exposure may increase the risk of cancer.
Special handling:
• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority.
Other warnings/precautions:
• Experienced staff: Images should only be interpreted by specially trained personnel.
• Limitations: A positive scan does not establish a diagnosis of Alzheimer disease or other cognitive disorders. Safety and effectiveness have not been established for predicting the development of a neurological condition (eg, dementia) or monitoring responses to therapy. Image interpretation provides an estimate of the brain β-amyloid plaque density; it does not determine clinical diagnosis.
• Risk for misinterpretation and errors: The use of clinical information in the interpretation of images has not been evaluated and may lead to errors. Scan results are indicative of the brain neuritic amyloid plaque content only at the time of imaging. A negative scan result does not preclude the development of brain amyloid in the future.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Intravenous:
Amyvid: 500-1900 MBQ/ML (1 ea) [contains alcohol, usp]
No
Solution (Amyvid Intravenous)
500-1900 mbq/ml (per each): $3,428.88
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
IV: Administer as a single intravenous bolus in a total volume of 10 mL or less; do not dilute. Following injection, flush with NS to ensure full delivery of dose. Administer through a short IV catheter (≤1.5 inches) to minimize potential drug adsorption to the catheter (may adhere to longer tubing/catheters). Initiate 10-minute PET image 30 to 50 minutes after injection. Patient should remain supine with brain centered in the PET scanner field of view; stabilize head to reduce movement if necessary.
Radiopharmaceutical; use appropriate precautions for handling and disposal. Waterproof gloves should be worn and effective shielding should be used during handling and administration.
Radioimaging: Radioactive agent for positron emission tomography (PET) imaging estimation of beta-amyloid neuritic plaque density in the brain of patients being evaluated for cognitive decline (eg, Alzheimer disease)
Florbetapir F18 may be confused with Flutemetamol F 18
Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.
None known.
There are no known significant interactions.
Evaluate pregnancy status prior to administration in females of reproductive potential.
Animal reproduction studies have not been conducted. Radiopharmaceuticals have the potential to cause fetal harm.
It is not known if florbetapir F18 is present in breast milk.
According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother; to minimize potential exposure to the infant, breast milk can be pumped and discarded, and alternate infant nutrition be used for 24 hours after drug administration.
Florbetapir F18 binds to β-amyloid plaques; the F18 isotope produces a positron signal that is detected by a PET scanner.
Distribution: <5% of total dose present in blood 20 minutes post administration; <2% of total dose present in blood 45 minutes post administration
Half-life elimination: Florbetapir F18: ~110 minutes
Excretion: Predominately through biliary/gastrointestinal tract
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
